CR7804A - Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico - Google Patents

Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico

Info

Publication number
CR7804A
CR7804A CR7804A CR7804A CR7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A
Authority
CR
Costa Rica
Prior art keywords
treatment
syndrome
myelodisplasic
acute leukemia
combined therapy
Prior art date
Application number
CR7804A
Other languages
English (en)
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR7804A publication Critical patent/CR7804A/es

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan metodos de tratamiento y combinaciones farmaceuticas para el tratamiento de la leucemia aguda, tales como leucemia mielogenosa aguda y sindrome displasico. Los metodos de tratamiento y combinaciones farmaceuticas emplean un conjugado citotoixico de anti-CD33 en comnbinacion con la menos un compuesto seleccionado del grupo que consiste de una antraciclina y un analogo del nucleosido de primidina o purina.
CR7804A 2002-11-06 2005-04-25 Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico CR7804A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
CR7804A true CR7804A (es) 2008-10-29

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7804A CR7804A (es) 2002-11-06 2005-04-25 Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico

Country Status (10)

Country Link
EP (1) EP1575582A4 (es)
JP (1) JP2006508119A (es)
CN (1) CN1720044A (es)
AU (2) AU2002348178A1 (es)
BR (1) BR0215935A (es)
CA (1) CA2504611A1 (es)
CR (1) CR7804A (es)
MX (1) MXPA05004711A (es)
NO (1) NO20052009L (es)
WO (1) WO2004043461A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977320B2 (en) 2004-10-29 2011-07-12 The Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
CA2614321A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ATE521366T1 (de) * 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
PT2120568T (pt) * 2007-02-16 2017-12-04 Celator Pharmaceuticals Inc Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
WO2010024374A1 (ja) 2008-08-29 2010-03-04 学校法人北里研究所 Ｄｎａメチル化阻害剤の薬剤効果検出方法
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
IL271475B2 (en) * 2017-06-22 2023-09-01 Servier Lab Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
BR112021014625A2 (pt) * 2019-01-28 2021-10-05 Board Of Regents, The University Of Texas System Método para tratar uma doença em um sujeito mamífero, método para reduzir ou eliminar uma ou mais mutações ou anormalidades citogenéticas nas células cancerosas de um sujeito com câncer, método para diagnosticar um sujeito com uma doença proliferativa responsiva à terapia de quelação, método para diagnosticar e tratar um sujeito com uma doença proliferativa responsiva à terapia de quelação, composição farmacêutica ou combinação farmacêutica, quelante de metal, terapia anticâncer, e antioxidante e/ou mineral
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
CA3199623A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy
WO2025214401A1 (zh) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 抗体药物偶联物、组合物及其用途和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
EP1309627B1 (en) * 2000-08-08 2009-09-30 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia with naked anti-nca-90 antibody

Also Published As

Publication number Publication date
AU2002348178A1 (en) 2004-06-03
CN1720044A (zh) 2006-01-11
NO20052009L (no) 2005-06-27
CA2504611A1 (en) 2004-05-27
MXPA05004711A (es) 2005-08-03
AU2010201113A1 (en) 2010-04-15
WO2004043461A1 (en) 2004-05-27
NO20052009D0 (no) 2005-04-25
EP1575582A4 (en) 2009-03-11
JP2006508119A (ja) 2006-03-09
BR0215935A (pt) 2005-08-09
EP1575582A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
AR027355A1 (es) Acidos tiazolidincarboxilicos
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
CL2008002139A1 (es) Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer.
CL2003002786A1 (es) Composicion liofilizada que comprende i) una epotilona y ii) manitol o una ciclodextrina y composicion liofilizada que los comprende reconstituida con solvente, util como citotoxico en el tratamiento de tumores.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
CR11687A (es) Terapia de combinación de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada
MX368013B (es) Tratamiento de cáncer.
BR0215935A (pt) Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
CL2009001170A1 (es) Composicion farmaceutica para administracion oral que comprende 5-azacitidina de liberacion inmediata sin recubrimiento enterico; y su uso para el tratamiento de una enfermedad asociada a la proliferacion anormal de celulas, tal como sindrome mielodisplasico, leucemia mielogena aguda y cancer de pulmon, entre otros.
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
AR013269A1 (es) Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
CR9846A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
WO2008101214A3 (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
AR047988A1 (es) Combinaciones antineoplásicas de cci-779 y rituximab
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
ECSP034766A (es) Una combinacion que comprende combretastatina y agentes anticancerigenos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)